Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tripartite motif-containing protein 51 (TRIM51) is a member of the TRIM (tripartite motif-containing) protein family, which is characterized by the presence of a RING finger domain, one or two B-box zinc finger domains, a coiled-coil region, and, in group 2 TRIM proteins like TRIM51, a C-terminal SPRY (SPla and the ryanodine receptor) domain, also called PRYSPRY[1]. Most TRIM proteins, including TRIM51, are believed to function as E3 ubiquitin ligases, conferring substrate specificity in the ubiquitin-proteasome system, thus participating in ubiquitination and regulation of protein stability; TRIM proteins also mediate protein–protein interactions and may play roles in cellular defense, although TRIM51-specific functions are not well elucidated[1][3]. #### Additional details and context - **Family and structure:** - The TRIM family is large and involved in diverse processes, especially in cellular regulation and immune function[1][3]. - TRIM51, by homology, contains the canonical tripartite motif (RING–B-box–coiled-coil) and a SPRY domain at the C-terminus typical of group 2 TRIM proteins[1]. - The SPRY domain may confer the ability to interact with various protein partners[2][4]. - **Functionality:** - Most TRIM proteins possess E3 ubiquitin ligase activity (mediating ubiquitination), a function inferred for TRIM51 from its conserved domains, but TRIM51-specific substrate(s) and cellular roles remain uncharacterized in current biomedical literature[3]. - Functions ascribed to the TRIM family at large include antiviral defense, immune regulation, and signaling modulation, but TRIM51-specific experiment-based functions are not described in accessible primary references[1][3]. - **Therapeutic relevance:** - No known drugs or experimental inhibitors/modulators are identified for TRIM51. - TRIM51 is not classified as a canonical therapeutic target (e.g., receptor, enzyme, clinically actionable protein) in current biomedical and chemoinformatics databases. - No evidence is available from the search that TRIM51 is used as a biomarker or presents known safety concerns. - **Aliases and alternative names:** - Alternative gene and protein names include **SPRYD5**, **TRIM51A**, and **SPRY domain-containing protein 5**. - **Summary:** - TRIM51 is a structurally conserved member of the TRIM family likely functioning as an E3 ubiquitin ligase, but its substrate specificity, expression pattern, and disease relevance are unreported or uncharacterized in available mainstream sources[1][3]. There are no records of drugs, disease associations, or known adverse implications linked directly to TRIM51. If further specificity about this protein’s role in pathophysiology, as a drug target, or in biomarker development emerges in the literature, those attributes would need to be added; as of now, such details are not established in major data sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tripartite motif-containing protein 51 (TRIM51).